Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Three individuals did not take any medication, whilst four took one or more of the following; Allopurinol, Vitamin D, Bisphosphonate (Table 1).Participant characteristics, ordered by V̇O2peak (from highest to lowest)ParticipantPatient demographicsClinical CharacteristicsDietary information and medicationsGenderAge (years)Height (cm)Body Mass (kg)Cardiac hypertrophy (Y/N)hepatomegaly (Y/N)Creatine kinase (RR: 26 to 140 IU/L)Triglycerides (mmol/L)Higher protein dietProtein supplementUCCSMedication1M27181.081.4Y*Y65921.2YNYA2F28173.173.3NY6411.1NNNNone3M26193.280.6NY38421.6YYNA, D4M48180.369.5NY17562.2YY (Int)NB, D5F50173.981.1NY12661.4YNNNone6F45162.378.9Y#N24421.1NNNNone7M32188.0112NY26821.5YYYDMean (SD): 37 (11)179 (10): : 2746 (1987)1.4 (0.4): : : : Median (IQ range): 80.6 (8.0): : : : : : : Int, Intermittent; Cardiac hypertrophy: *Y1, Maximal wall thickness 14 mm (asymmetric septal), #Y6, Maximal wall thickness 13 mm (basal septal); UCCS: uncooked cornstarch: Y, 50 g nightly; A, Allopurinol; D, Vitamin D; B, Bisphosphonate

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Aerobic capacity and skeletal muscle characteristics in glycogen storage disease IIIa: an observational study

Source: Article title.

In this descriptive study, participants were recruited from the Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London and the Department of Adult Inherited Metabolic Disease, St Thomas’ Hospital, London.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Aerobic capacity and skeletal muscle characteristics in glycogen storage disease IIIa: an observational study

Observational study · Orphanet Journal of Rare Diseases · 2022

Original publication title

Aerobic capacity and skeletal muscle characteristics in glycogen storage disease IIIa: an observational study

Philip J. Hennis; Elaine Murphy; Rick I. Meijer; Robin H. Lachmann; Radha Ramachandran; Claire Bordoli; Gurinder Rayat; David J. Tomlinson

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

V̇O2peak and knee extension strength are lower in individuals with GSD IIIa than predicted based on their demographic data. Patients with higher physical capacity have superior muscle size and structure characteristics and higher health-related quality of life, than those with lower physical capacity. This study provides normative values of these important markers of physical capacity.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Individuals with glycogen storage disease IIIa (GSD IIIa) (OMIM #232400) experience muscle weakness and exercise limitation that worsen through adulthood. However, normative data for markers of physical capacity, such as strength and cardiovascular fitness, are limited. Furthermore, the impact of the disease on muscle size and quality is unstudied in weight bearing skeletal muscle, a key predictor of physical function. We aim to produce normative reference values of aerobic capacity and strength in individuals with GSD IIIa, and to investigate the role of muscle size and quality on exercise impairment.

Source: Background

Abstract: Results

Peak oxygen uptake (V̇O2peak) was lower in the individuals with GSD IIIa than predicted based on demographic data (17.0 (9.0) ml/kg/min, 53 (24)% of predicted, p = 0.001). Knee extension maximum voluntary contraction (MVC) was also substantially lower than age matched predicted values (MVC: 146 (116) Nm, 57% predicted, p = 0.045), though no difference was found in MVC relative to body mass (1.88 (2.74) Nm/kg, 61% of predicted, p = 0.263). There was a strong association between aerobic capacity and maximal leg strength (r = 0.920; p = 0.003).

Substantial inter-individual variation was present, with a high physical capacity group that had normal leg strength (MVC), and relatively high V̇O2peak, and a low physical capacity that display impaired strength and substantially lower V̇O2peak. The higher physical capacity sub-group were younger, had larger Vastus Lateralis (VL) muscles, greater muscle quality, undertook more physical activity (PA), and reported higher health-related quality of life.

Source: Results

Abstract: Conclusions

V̇O2peak and knee extension strength are lower in individuals with GSD IIIa than predicted based on their demographic data. Patients with higher physical capacity have superior muscle size and structure characteristics and higher health-related quality of life, than those with lower physical capacity. This study provides normative values of these important markers of physical capacity.

Source: Conclusions
Authors’ abstract

Background

Individuals with glycogen storage disease IIIa (GSD IIIa) (OMIM #232400) experience muscle weakness and exercise limitation that worsen through adulthood. However, normative data for markers of physical capacity, such as strength and cardiovascular fitness, are limited. Furthermore, the impact of the disease on muscle size and quality is unstudied in weight bearing skeletal muscle, a key predictor of physical function. We aim to produce normative reference values of aerobic capacity and strength in individuals with GSD IIIa, and to investigate the role of muscle size and quality on exercise impairment.

Results

Peak oxygen uptake (V̇O2peak) was lower in the individuals with GSD IIIa than predicted based on demographic data (17.0 (9.0) ml/kg/min, 53 (24)% of predicted, p = 0.001). Knee extension maximum voluntary contraction (MVC) was also substantially lower than age matched predicted values (MVC: 146 (116) Nm, 57% predicted, p = 0.045), though no difference was found in MVC relative to body mass (1.88 (2.74) Nm/kg, 61% of predicted, p = 0.263). There was a strong association between aerobic capacity and maximal leg strength (r = 0.920; p = 0.003).

Substantial inter-individual variation was present, with a high physical capacity group that had normal leg strength (MVC), and relatively high V̇O2peak, and a low physical capacity that display impaired strength and substantially lower V̇O2peak. The higher physical capacity sub-group were younger, had larger Vastus Lateralis (VL) muscles, greater muscle quality, undertook more physical activity (PA), and reported higher health-related quality of life.

Conclusions

V̇O2peak and knee extension strength are lower in individuals with GSD IIIa than predicted based on their demographic data. Patients with higher physical capacity have superior muscle size and structure characteristics and higher health-related quality of life, than those with lower physical capacity. This study provides normative values of these important markers of physical capacity.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13023-022-02184-1.

Publication and source details

Original title: Aerobic capacity and skeletal muscle characteristics in glycogen storage disease IIIa: an observational study

Philip J. Hennis; Elaine Murphy; Rick I. Meijer; Robin H. Lachmann; Radha Ramachandran; Claire Bordoli; Gurinder Rayat; David J. Tomlinson

Orphanet Journal of Rare Diseases · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/100002632association for glycogen storage diseasehttp://dx.doi.org/10.13039/501100012317uclh biomedical research centre

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T10:17:55.835915+00:00

DOI: 10.1186/s13023-022-02184-1 · PMC8802498